Exclusive Summary

• - Guideline-recognized rapid IV vasodilator covering hypertensive emergencies, acute heart failure, and intraoperative controlled hypotension.
• - Ready-to-use premix in 0.9% NaCl (10 mg/50 mL, 20 mg/100 mL, 50 mg/100 mL) reduces compounding risk and turnaround time versus products requiring on-site dilution.
• - US-registered and offered for Distribution, enabling faster multi-country market access and tender onboarding.
• - Off-patent with broad generic entry, typically delivering ~50–80% savings vs originator pricing.
• - Demand anchored by ~1.28 billion people with hypertension, ~313 million surgeries/year, and >1 million hypertensive AHF admissions suitable for IV vasodilators.